Psoriasis and Vitamin D3: A Review of Our Experience

Archives of Dermatology

Volumn 125, Issue 2, 1989, Pages 231-234

  Morimoto, Shigeto ^a,c   Yoshikawa, Kunihiko ^b,c  

^a Tokyo Medical University   (Japan)

^b Departments of Dermatology ^*  (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; COLECALCIFEROL;

CLINICAL ARTICLE; HUMAN; HUMAN CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; TOPICAL DRUG ADMINISTRATION; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; PATHOLOGY; RANDOMIZATION; TIME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; CALCITRIOL; CALCIUM; CHOLECALCIFEROL; FEMALE; HUMAN; MALE; MIDDLE AGE; PSORIASIS; RANDOM ALLOCATION; TIME FACTORS;

EID: 0024615825     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1989.01670140083015     Document Type: Article

References (15)

1. Weinstein GD, Frost P: Abnormal cell proliferation in psoriasis. J Invest Dermatol 1968;51:254–259.
2. Stewart AF, Battaglini-Sabetta J, Millstone L: Hypocalcemia-induced pustular psoriasis of von Zumbush: New experience with old syndrome. Ann Intern Med 1984;5:677–680.
3. Risum G: Psoriasis exacerbated by hypoparathyroidism with hypocalcemia. Br J Dermatol 1973;89:309–312.
4. Feldman D, Chen T, Hirst M, et al: Demonstration of 1,25-dihydroxyvitamin D, receptors in human skin biopsies. J Clin Endocrinol Metab 1980;51:1463–1465.
5. Clemens TL, Adams JS, Horiuchi N, et al: Inhibition of 1,25-dihydroxyvitamin D, with keratinocytes and fibroblasts from skin of normal subjects and subjects with vitamin-D-deficient rickets type II: A model for study of the mode of action of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1983;56:824–830.
6. Hosomi J, Hosoi J, Abe E, et al: Regulation of terminal differentiation of cultured mouse epidermal cells by 1α,25dihydroxyvitamin D3. Endocrinology 1983;113:1950–1957.
7. Morimoto S, Kumahara Y: A patient with psoriasis cured by 1α-hydroxyvitamin D3. Med J Osaka Univ 1985;35:51–54.
8. Morimoto S, Yoshikawa K, Kozuka T, et al: An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 1985;115:421–429.
9. Fredriksson T, Petterson U: Severe psoriasis, oral therapy with a new retinoid. Dermatologica 1978;157:238–244.
10. Shimotsuji Y, Seino Y: Competitive protein binding assay for 25-hydroxycholecalciferol. Methods Enzymol 1980;67:466–472.
11. Lee S, Morimoto S, Onishi T, et al: Normal serum 1,25-dihydroxyvitamin D in patients with medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1982;55:361–363.
12. Morimoto S, Tsuji M, Okada Y, et al: The effect of oestrogens on human calcitonin secretion after calcium infusion in elderly female subjects. Clin Endocrinol 1980;13:135–143.
13. Abe E, Miyaura C, Sakagami H, et al: Differentiation of mouse myeloid leukemia cells induced by 1α,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981;78:4990–4994.
14. MacLaughlin JA, Gang W, Taylor D, et al: Cultured psoriatic fibroblasts from involved and uninvolved sites have a partial but not absolute resistance to the proliferation-inhibition activity of 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1985; 82:5409–5412.
15. Bikle DD, Nemanic MK, Gee E, et al: 1,25-Dihydroxyvitamin D, production by human keratinocytes. J Clin Invest 1986;78:557–566.